Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06554600
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-07
Brief Title:
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin Bendamustine and Rituximab in the Treatment of RelapsedRefractory Diffuse Large B-cell Lymphoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Efficiency and Safety of Zanubrutinib in Combination With Polatuzumab Vedotin Bendamustine and Rituximab in the Treatment of RelapsedRefractory Diffuse Large B-cell Lymphoma a Prospective Single-arm Multicenter Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective multicenter single-arm open phase II study to explore the efficacy and safety of Zanubrutinib in combination with Polatuzumab Vedotin bendamustine and rituximab Polo-ZBR in subjects with relapsedrefractory diffuse large B-cell lymphoma Subjects with relapsedrefractory DLBCL who met the inclusionexclusion criteria were screened and treated with 4 courses of Pola-ZBR regimen after signing informed consent Subjects achieving PR or CR were consolidated with autologous transplantation consolidation or the original regimen for 2 additional courses and then given Zanubrutinib maintenance therapy for 1 year The final follow-up was observed until 2 years after enrollment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None